Compare Meta Platforms Inc (META) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs Merck & Co., Inc. — how do they compare? Meta Platforms Inc trades at $723.23 (market cap $1.84T), while Merck & Co., Inc. trades at $144.64 (market cap $351.28B). The key difference: Meta Platforms Inc is far larger — about 5.2× Merck & Co., Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Meta Platforms Inc for 127 Days and Merck & Co., Inc. for 98 Days on average.
| META | MRK | |
|---|---|---|
Market Cap | $1.84T | $351.28B |
Volume | 15,887,049 | 7,969,665 |
Sector | Media | Health |
52-Week High | $777.59 | $156.43 |
52-Week Low | $525.72 | $82.49 |
Typical Hold Time | 127 Days | 98 Days |
Enterprise Value | $1.86T | $398.04B |
Dividend Yield | 0.29% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
META stock trades at $721.31, down 2.38% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish trend per moving averages, with key support at $719 and resistance at $726. Recent financials reveal strong revenue growth to $201.0B in 2025 and a net income margin of 29.84%, though Q2 2026 EPS missed expectations. The launch of the Muse Spark AI model and a $21B deal with CoreWeave highlight strategic initiatives driving investor optimism, countered by ongoing legal challenges over youth addiction.
The outlook for META remains positive with an 80% analyst buy rating and a consensus price target of $781, suggesting ~8% upside. Key opportunities include AI monetization and robust cash flow growth, while risks involve regulatory lawsuits and high capital expenditures. Investors should weigh strong profitability against legal and competitive pressures in the social media sector.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
